Why the study?
Does ticagrelor compared to clopidogrel have different relative safety and efficacy based on diabetes status in Korean ACS patients undergoing early invasive management?
Does ticagrelor compared to clopidogrel have different relative safety and efficacy based on diabetes status in Korean ACS patients undergoing early invasive management?
The relative safety and efficacy of ticagrelor versus clopidogrel in Korean ACS patients undergoing early invasive management is consistent regardless of diabetes status.
Answers are grounded in this paper and cite their sources.
Supports consistent ticagrelor-clopidogrel choice irrespective of diabetes in Korean ACS; leaves open generalizability beyond this Level 3 cohort.
In Korean ACS patients undergoing early invasive management, diabetes status did not affect the relative safety and efficacy of ticagrelor and clopidogrel. (Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/Korean Patients With Acute Coronary Syndromes Intended for Invasive Management [TICA KOREA]; NCT02094963).
No takes yet. Share an insight, caveat, or question.
Choi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: